Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by 1998novlon Jan 12, 2021 6:19pm
150 Views
Post# 32279104

RE:RE:RE:RE:RE:RE:RE:Excellent

RE:RE:RE:RE:RE:RE:RE:Excellent

Thanks JFM, always enjoy the insight. 

I think many on this board including SPCEO are confusing TH for Berkshire Hatahway or some other massive conglomerate with significant earnings. When you are Biotech, you get diluted. Why is that so hard to swallow?  The only thing that comes to mind is most don't have the funds to increase their position by 32% today. Last week they praise the company for rolling out 2 FDA approved programs and increasing sales and today they forgot that and don't want to increase their holdings by 32%, but rather sell. Seems backwards to me. I get it, dilution sucks, but welcome to Biotech.., how that's surprising to so many posters here is shocking to me. Maybe you didn't know wha let you were buying and that is compounded by the lack of trust you have with management. Whatever it's is, TH isn't going anywhere. If you complain the stock could have hit $40 and now will only make it to $28, tough luck! We are also not going repeat 2012. Smart Money buys on events like this. 

<< Previous
Bullboard Posts
Next >>